Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 4/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5225036 | 0.84 | LMNA (0.41) | ALDH1A1SMN1; SMN2LTA4HKCNH2HRH3 | |
| SCHEMBL5226728 | 0.84 | MAPT (0.43) | LTA4HKCNH2 | |
| SCHEMBL509887 | 0.80 | PDE10A (0.39) | ALDH1A1KDM4ESMN1; SMN2KCNH2NPC1 | |
| SCHEMBL509996 | 0.75 | KCNH2 (0.50) | ALDH1A1KCNH2HRH3TSHR | |
| SCHEMBL5226802 | 0.75 | KCNH2 (0.50) | ALDH1A1SMN1; SMN2KCNH2 | |
| SCHEMBL509154 | 0.74 | KCNH2 (0.48) | ALDH1A1KCNH2HRH3HSD17B10 | |
| SCHEMBL508731 | 0.74 | P2RX7 (0.41) | KCNH2 | |
| SCHEMBL10254128 | 0.74 | P2RX7 (0.41) | ALDH1A1KCNH2 | |
| SCHEMBL1347408 | 0.73 | KCNH2 (0.48) | ALDH1A1KDM4ESMN1; SMN2LTA4HKCNH2 | |
| SCHEMBL508346 | 0.73 | KCNH2 (0.54) | KCNH2HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1377556-B1 | PYRAZOLE DERIVATIVES FOR TREATING HIV | PFIZER LTD (GB) | 2007-04-04 | — | — | EP | claimed |
| EP-1762567-A1 | Pyrazole derivatives for treating HIV | Pfizer Limited (GB) | 2007-03-14 | — | — | EP | claimed |
| US-20030100554-A1 | Pyrazole derivatives | JONES LYN HOWARD (GB) | 2003-05-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030100554-A1 | Pyrazole derivatives | REV1, SARS1, CYP2F1 | ALDH1A1 385/4885GAA 710/4885KDM4E 2816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.